We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preliminary evidence of effects of potassium chloride on a metabolomic path to diabetes and cardiovascular disease.
- Authors
Chatterjee, Ranee; Davenport, Clemontina A.; Kwee, Lydia; D'Alessio, David; Svetkey, Laura P.; Lin, Pao-Hwa; Slentz, Cris A.; Ilkayeva, Olga; Johnson, Johanna; Edelman, David; Shah, Svati H.
- Abstract
Introduction: Low potassium intake can affect cardiovascular disease (CVD) risk and cardiometabolic risk factors. Objective: We hypothesize that potassium chloride (KCl) supplementation can improve cardiovascular risk metabolomic profile. Methods: In this secondary analysis of a pilot randomized clinical trial (RCT) of 26 participants with prediabetes randomized to KCl or placebo, we performed targeted mass-spectrometry-based metabolomic profiling on baseline and 12-week (end-of-study) plasma samples. Principal component analysis (PCA) was used to reduce the many correlated metabolites into fewer, independent factors that retain most of the information in the original data. Results: Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11). Conclusions: KCl supplementation may improve circulating BCAA levels, which may reflect improvements in overall cardiometabolic risk profile. Clinical Trials Registry: Clinicaltrials.gov identifier: NCT02236598; https://clinicaltrials.gov/ct2/show/NCT02236598.
- Subjects
POTASSIUM chloride; CARDIOVASCULAR diseases; CLINICAL trial registries; PRINCIPAL components analysis; AMINO acids; DIABETES
- Publication
Metabolomics, 2020, Vol 16, Issue 7, p1
- ISSN
1573-3882
- Publication type
Article
- DOI
10.1007/s11306-020-01696-w